The global aspirin market is anticipated to grow at a considerable CAGR of 3.6 % during the forecast period (2023-2030). Aspirin can be used to treat a wide range of diseases, including cancer, diabetes, cryptococcal infection, and abnormalities of the nervous system, owing to it has an impact on both Cyclooxygenase (COX)-dependent and Cyclooxygenase COX-independent pathways. Aspirin as one of the ingredients for creating specialized healthcare products such as hydrogels. The growing active pharmaceutical ingredient (API) industry would further stimulate the market growth of acetylsalicylic acid (commonly known as Aspirin) as an ingredient in therapeutic formulations. It is an analgesic and is used to get relief from acute pain. It is highly effective against muscle pain, bloating, skin irritation, gastric distension. It is also used for the treatment of migraine. It is effective against cluster headaches.
Browse the full report description of “Aspirin Market Size, Share & Trends Analysis Report by Route of Administration (Oral, Rectal, Parenteral), by Dosage Form (Tablets, Intravenous Injections, Capsules, and Others), by Applications (Pain, Deep vein Thrombosis, Fever and Inflammation and Others), by Product Type (Alone, Combination Products), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/aspirin-market
Owing to such benefits, there is spike in various drug approvals activities across the globe, which is the primary factor supporting the market growth. For Instance, in March 2023, Vazalore, PLx Pharma's liquid-filled aspirin capsule, received FDA approval. In several ways, the formulation surpassed enteric-coated and immediate-release aspirin in clinical testing. According to FDA, in individuals with cardiovascular disease or who have already experienced a heart attack or stroke, aspirin has been demonstrated to be beneficial when administered daily to reduce the risk of heart attack, clot-related strokes, and other blood flow issues.
In March 2023, Janssen Pharmaceutical Companies of Johnson & Johnson announced for patients with peripheral arterial disease (PAD), XARELTO® is the first and only anticoagulant that has been licensed for use in conjunction with aspirin to lower the risk of significant thrombotic vascular events. Further, in February 2023, Bayer launched a new aspirin advertising campaign that links heart health and the stress of sports fanaticism. Additionally, Bayer is working with NBC Sports and Bally Sports to develop multimedia content and regional media partnerships with TV personalities and sports figures.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Route of Administration
o By Dosage Form
o By Treatment
o By Product Type
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Bayer AG, Cardinal Health, LNK International, Inc., Mayne Pharma Group Ltd., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Aspirin Market Report Segment
By Route of Administration
By Dosage Form
By Applications
By Product Type
By Distribution Channel
Global Aspirin Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/aspirin-market